Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

J&J COVID-19 vaccine could be available in Europe in April - source

01/13/2021 | 02:27pm EST
FILE PHOTO: Vials and medical syringe are seen in front of J&J logo in this illustration

BRUSSELS (Reuters) - Johnson & Johnson could deliver the first doses of its COVID-19 vaccine to Europe in April, an EU official told Reuters on Wednesday after a top lawmaker said the U.S. healthcare company was likely to seek EU regulatory approval in February.

Clinical data on the vaccine has been assessed by the European Medicines Agency (EMA) since Dec. 1 under a rolling review to speed up possible approval.

A senior EU official, who is involved in negotiations with vaccine makers and spoke on condition of anonymity, said the J&J shot could be available from April 1 in Europe [B5N2B301Q].

Earlier on Wednesday, an EU lawmaker said J&J could seek EU approval for its one-shot vaccine in February.

"EU Health Commissioner Stella Kyriakides announced during our (EU lawmakers) group meeting this morning that the vaccine manufacturer Johnson & Johnson is likely to submit an application for approval to the EU for their vaccine in February," said Peter Liese, who speaks on health matters for the EU's centre-right group, the assembly's largest.

Following Liese's comments, a spokesman for Kyriakides said: "We cannot give any precise indications regarding an application for conditional marketing authorisation, but we of course hope that an application could be submitted in the coming weeks."

EMA, in a statement, said "a date for submission of a marketing authorisation application has not yet been confirmed."

Asked about the timeline described by the EU source and the lawmaker, which appeared to be slightly behind expectations for the vaccine in the United States, a J&J spokesman said talks with regulators were underway, but it was premature to get into the specifics of supply plans at this stage.

J&J Chief Scientific Officer Dr. Paul Stoffels told Reuters the drugmaker expects to have clear data on how effective its vaccine is by the end of this month or early February and was on track for a U.S. rollout in March.

The EU drugs regulator had said in December it expected the J&J to apply in the first quarter of this year.

It took EMA 20 days to approve the vaccine developed by BioNTech SE and Pfizer Inc, and just over a month to authorise the Moderna Inc shot after their applications were submitted in early December. The two vaccines are so far the only ones approved in the EU, while AstraZeneca submitted its application on Tuesday.

"If all goes well, we will already have the fourth corona vaccine available in a few weeks," Liese added.

The EU has booked 200 million doses of the J&J vaccine and has an option to order another 200 million shots. The J&J vaccine is administered as a single shot, while those from Moderna and Pfizer/BioNTech require two doses three or four weeks apart for full protection.

The EU has invested about 360 million euros ($438 million) to secure the J&J vaccine with a downpayment that would need to be complemented with payments by EU governments willing to buy the vaccine after approval.

The U.S. government secured 100 million doses from the company for $1 billion in an August agreement, with an option to buy an additional 200 million doses.

($1 = 0.8216 euros)

(Reporting by Francesco Guarascio; Additional reporting by Julie Steenhuysen in Chicago; Editing by Jason Neely, Louise Heavens and Bill Berkrot)

By Francesco Guarascio


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
BIONTECH SE 2.86% 108.44 Delayed Quote.33.02%
Latest news "Economy & Forex"
04:00aIMF urges deficit control in Tunisia even as protesters demand jobs
RE
01:34aECLAC ECONOMIC COMMISSION FOR LATIN AMERICA AND : Celebrates Prompt Entry into Force of the Escazú Agreement and Highlights the Region's Commitment to Sustainable Development and Human Rights
PU
01/22CENTRAL BANK OF SRI LANKA : Discretionary Payments of Licensed Banks
PU
01/22Biden, Canada's Trudeau to meet next month, collaborate on vaccines, medical supplies
RE
01/22FEDERAL TRADE COMMISSION : What to know about the second round of Economic Impact Payment (EIP) checks and cards
PU
01/22NETFLIX, PROCTER & GAMBLE, INTEL : Stocks That Defined the Week
DJ
01/22CENTRAL PEOPLE GOVERNMENT OF PEOPLE RE : Xi stresses strict Party governance for 14th Five-Year Plan period
PU
01/22WORLD BANK : Nicaragua to Receive Emergency Funding Following Devastation Left by Eta and Iota
PU
01/22Morgan Stanley CEO's annual pay rises by over 20%
RE
01/22Yellen nomination sails through Senate panel; final vote set for Monday
RE
Latest news "Economy & Forex"